TRAIL-induced apoptosis: between tumor therapy and immunopathology - PubMed (original) (raw)
Review
TRAIL-induced apoptosis: between tumor therapy and immunopathology
Nadia Corazza et al. Ann N Y Acad Sci. 2009 Aug.
Abstract
The death ligand members of the tumor necrosis factor (TNF) family are potent inducers of apoptosis in a variety of cell types. In particular, TNF-related apoptosis-inducing ligand (TRAIL) has recently received much scientific and commercial attention because of its potent tumor cell-killing activity while leaving normal untransformed cells mostly unaffected. Furthermore, TRAIL strongly synergizes with conventional chemotherapeutic drugs in inducing tumor cell apoptosis, making it a most promising candidate for future cancer therapy. Increasing evidence indicates, however, that TRAIL may also induce or modulate apoptosis in primary cells. A particular concern is the potential side effect of TRAIL-based tumor therapies in the liver. In this review we summarize some of the recent findings on the role of TRAIL in tumor cell and hepatocyte apoptosis.
Similar articles
- GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial.
Jiang J, Liu X, Deng L, Zhang P, Wang G, Wang S, Liu H, Su Y. Jiang J, et al. Eur J Pharmacol. 2014 Oct 5;740:722-32. doi: 10.1016/j.ejphar.2014.06.002. Epub 2014 Jun 11. Eur J Pharmacol. 2014. PMID: 24929054 - [Recent advances for research on anti-tumor effects of TNF-related apoptosis-inducing ligand].
Yao GH, Hou YY. Yao GH, et al. Wei Sheng Yan Jiu. 2006 Jan;35(1):115-7. Wei Sheng Yan Jiu. 2006. PMID: 16598953 Review. Chinese. - Tumor suppressor XIAP-Associated factor 1 (XAF1) cooperates with tumor necrosis factor-related apoptosis-inducing ligand to suppress colon cancer growth and trigger tumor regression.
Tu SP, Sun YW, Cui JT, Zou B, Lin MC, Gu Q, Jiang SH, Kung HF, Korneluk RG, Wong BC. Tu SP, et al. Cancer. 2010 Mar 1;116(5):1252-63. doi: 10.1002/cncr.24814. Cancer. 2010. PMID: 20082449 - TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality.
Corazza N, Jakob S, Schaer C, Frese S, Keogh A, Stroka D, Kassahn D, Torgler R, Mueller C, Schneider P, Brunner T. Corazza N, et al. J Clin Invest. 2006 Sep;116(9):2493-9. doi: 10.1172/JCI27726. J Clin Invest. 2006. PMID: 16955144 Free PMC article. - Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
Ashkenazi A, Holland P, Eckhardt SG. Ashkenazi A, et al. J Clin Oncol. 2008 Jul 20;26(21):3621-30. doi: 10.1200/JCO.2007.15.7198. J Clin Oncol. 2008. PMID: 18640940 Review.
Cited by
- Model certainty in cellular network-driven processes with missing data.
Irvin MW, Ramanathan A, Lopez CF. Irvin MW, et al. PLoS Comput Biol. 2023 Apr 26;19(4):e1011004. doi: 10.1371/journal.pcbi.1011004. eCollection 2023 Apr. PLoS Comput Biol. 2023. PMID: 37099625 Free PMC article. - Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies.
Atilla PA, Atilla E. Atilla PA, et al. Transl Oncol. 2022 Aug;22:101459. doi: 10.1016/j.tranon.2022.101459. Epub 2022 May 23. Transl Oncol. 2022. PMID: 35617812 Free PMC article. Review. - The lncRNA CASC2 Modulates Hepatocellular Carcinoma Cell Sensitivity and Resistance to TRAIL Through Apoptotic and Non-Apoptotic Signaling.
Sun J, Xu H, Lei Z, Li Z, Zhu H, Deng Z, Yu X, Jin X, Yang Z. Sun J, et al. Front Oncol. 2022 Jan 25;11:726622. doi: 10.3389/fonc.2021.726622. eCollection 2021. Front Oncol. 2022. PMID: 35145900 Free PMC article. - Insight into the divergent role of TRAIL in non-neoplastic neurological diseases.
Gao S, Fang Y, Tu S, Chen H, Shao A. Gao S, et al. J Cell Mol Med. 2020 Oct;24(19):11070-11083. doi: 10.1111/jcmm.15757. Epub 2020 Aug 22. J Cell Mol Med. 2020. PMID: 32827246 Free PMC article. Review. - Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies.
Cheng J, Zhao L, Zhang Y, Qin Y, Guan Y, Zhang T, Liu C, Zhou J. Cheng J, et al. Front Oncol. 2019 Nov 21;9:1237. doi: 10.3389/fonc.2019.01237. eCollection 2019. Front Oncol. 2019. PMID: 31824840 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources